Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Sponsor: Terremoto Biosciences Inc.
Summary
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
Official title: A Phase 1 Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-12-15
Completion Date
2028-03
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
TER-1754
QD or BID, orally in 28-day cycles
Placebo
Number of tablets will be confirmed post Phase 1a
TER-1754
Phase 1b dose to be determined post Phase 1a
Locations (1)
Innovative Hematology, Inc.
Indianapolis, Indiana, United States